Comments
paul.nowak wrote: Matt, thanks for the comments. I made an error on the version of Plone. It's 2.5 Plone running on Zope 2.9x. In regards to the additional products, we have a skin installed and we have a product that we had custom developed for us that connects to a PostgreSQL database. We've looked at slow PostgreSQL queries causing problems and have not been able to find an issue. We've also tested for the case where the PostgreSQL server is down and have not been able to create an issue. We therefor...
Cloud Expo on Google News

SYS-CON.TV

2009 East
PLATINUM SPONSORS:
IBM
Smarter Business Solutions Through Dynamic Infrastructure
IBM
Smarter Insights: How the CIO Becomes a Hero Again
Microsoft
Windows Azure
GOLD SPONSORS:
Appsense
Why VDI?
CA
Maximizing the Business Value of Virtualization in Enterprise and Cloud Computing Environments
ExactTarget
Messaging in the Cloud - Email, SMS and Voice
Freedom OSS
Stairway to the Cloud
Sun
Sun's Incubation Platform: Helping Startups Serve the Enterprise
POWER PANELS:
Click For 2008 West
Event Webcasts
EntreMed to Present at the New York Society of Security Analysts Industry Conference

ROCKVILLE, Md., Nov. 25 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced today that a Company overview will be provided at the NYSSA 2008 Biotech and Specialty Pharmaceuticals Industry Conference, to be held at the Conference Facilities at the NYSSA, New York, December 2, 2008. Dane R. Saglio, Chief Financial Officer, will present on behalf of the Company. The presentation is scheduled for 1:35 p.m. (local time) and will be included in an archived web cast on the NYSSA web site after December 3, 2008. An electronic version of Mr. Saglio's presentation will be available on the Company's web site at www.entremed.com.

(LOGO: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO)

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1, an oral cell-cycle regulator with activity against the mTOR pathway, is currently in multiple Phase 2 clinical trials for cancer. ENMD-2076, a selective angiogenic kinase inhibitor, and ENMD-1198, a novel antimitotic agent are in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell cycle regulation, cell signaling and inflammation - processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at www.entremed.com and in various filings with the Securities and Exchange Commission.

    Ginny Dunn
    Associate Director
    Corporate Communications & Investor Relations
    EntreMed, Inc.
    240-864-2643

SOURCE EntreMed, Inc.

About PR Newswire
Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Cloud Developer Stories
GigaSpaces and GoGrid have been strategic partners for quite a while. This week, we jointly announced a new technology partnership aimed at offering Java and .NET as a PaaS solution. To further explain our combined solution, there is a webinar slotted for October 14th where Guy N...
I had the pleasure of not only attending the Cloud Computing Expo in Santa Clara, CA this week, staffing the booth and generally enjoying talking to a wide range of developers, technologists, vendors, partners and others, but I also was able to do a couple of interviews with Pete...
Big news on the Cloud Standards front, I was just informed that the International Organization for Standardization (ISO) - JTC 1 have formed a new Subcommittee (SC) at their Plenary last week that includes...
The new widgetry features multi-cluster support and enhanced concurrency management to improve scaling so users can seamlessly overlay their Eucalyptus cloud on top of virtually any existing IT infrastructure, regardless of size or configuration. Eucalyptus is meant for implement...
It says Traffic Server enables the session management, authentication, configuration management, load balancing and routing of an entire cloud computing stack. It’s supposed to offer fast, reliable and scalable access to cached online content and speed responses to requests for s...
Subscribe to the World's Most Powerful Newsletters
Subscribe to Our Rss Feeds & Get Your SYS-CON News Live!
Click to Add our RSS Feeds to the Service of Your Choice:
Google Reader or Homepage Add to My Yahoo! Subscribe with Bloglines Subscribe in NewsGator Online
myFeedster Add to My AOL Subscribe in Rojo Add 'Hugg' to Newsburst from CNET News.com Kinja Digest View Additional SYS-CON Feeds
Publish Your Article! Please send it to editorial(at)sys-con.com!

Advertise on this site! Contact advertising(at)sys-con.com! 201 802-3021

SYS-CON Featured Whitepapers
ADS BY GOOGLE

Breaking Cloud Computing News